Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) subsidiary Fosun Pharma's (Xuzhou) drug registration application for the Levosalbutamol Hydrochloride Nebuliser Solution was accepted by the National Medical Products Administration of China, a Friday Hong Kong bourse filing said.
The drug is a chemical drug used for the treatment or prevention of bronchospasm in adults and children 6 years and older.
The company, as of the end of 2024, has invested 4.54 million yuan in the research and development of the drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.